Ratings Patterson Companies, Inc. Börse Stuttgart

Equities

PD2

US7033951036

Real-time Estimate Tradegate Other stock markets 07:44:01 01/07/2024 BST			5-day change	1st Jan Change
22.5 ^EUR	+2.27%		-0.90%	-14.06%

06-20	Morgan Stanley Adjusts Price Target on Patterson Companies to $28 From $30, Maintains Equalweight Rating	MT
06-20	JPMorgan Adjusts Price Target on Patterson Companies to $29 From $30, Maintains Neutral Rating	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The stock, which is currently worth 2025 to 0.38 times its sales, is clearly overvalued in comparison with peers.
The company has a low valuation given the cash flows generated by its activity.
This company will be of major interest to investors in search of a high dividend stock.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company does not generate enough profits, which is an alarming weak point.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
PATTERSON COMPANIES, INC.	-14.06%	2.12B	-
ABBOTT LABORATORIES	-5.60%	181B	C+
MEDTRONIC PLC	-4.45%	101B	C
BECTON, DICKINSON AND COMPANY	-4.15%	67.54B	A
DEXCOM, INC.	-8.63%	45.09B	B-
CENCORA, INC.	+9.70%	44.37B	B-
HOYA CORPORATION	+5.36%	40.7B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+15.22%	29.85B	B
TERUMO CORPORATION	+10.26%	24.49B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-6.46%	23.99B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes